Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Featured Practice Guidelines
    • Urinary and male...

    Urinary and male genital tract infections-Standard Treatment Guidelines

    Written by supriya kashyap kashyap Published On 2017-03-27T13:36:25+05:30  |  Updated On 27 March 2017 1:36 PM IST
    Urinary and male genital tract infections-Standard Treatment Guidelines

    Infections of the urinary tract pose a serious health problem, also because of their frequent occurrence.


    Clinical and experimental evidence support that the ascent of micro-organisms within the urethra is the most commom pathway leading to urinary tract infections, especially for organisms of enteric origin (I.e Escherichia coli and other Enterobacteriaeae). This is a logical explanation for the greater frequency of UTIs in women than in men and the increased risk of infection following bladder catherisation or instrumentation.


    Ministry of Health and Family Welfare, Government of India has issued the Standard Treatment Guidelines for Urinary and male genital tract infections.
    Following are the major recommendations :

    Classification of Urinary and Male Genital Tract Infections


    For practical clinical reasons, urinary tract infections (UTIs) and male genital tract infections are classified according to entities with predominating clinical symptoms: (I) uncomplicated lower UTI (cystitis); (2) uncomplicated pyelonephritis; (3) complicated UTI with or without pyelonephritis; (4) Urosepsis; (5) urethritis; and (6) prostatitis, epididymitis, orchitis.

    Definitions


    the definitions of bacteriuria and pyuria are as follows: Significant bacteriuria in adults:

    • > 103 uropathogens/ml of midstream urine in acute uncomplicated cysitis in female;

    • > 104 uropathogens/ml of midstream urine in acute uncomplicated pyelonephritis in female;

    • > 104 uropathogens/ml of midstream urine of women or 104 uropathogens/ml of midstream urine in men (or in catheter, urine specimen in women) with complicated UTI.


    In a suprapubic bladder puncture specimen any count of bacteria is relevant.

    Asymptomatic bacteriuria (ABU)


    ABU is defined as two positive urine cultures taken more that 24h apart with 105 uropathogens/ml of the same bacterial strain.


    Pyuria


    The requirement for pyuria is 10 white blood cells per high power field in the resuspended sediment of a centrifuged aliquot of urine or per mm3 in unspun urine. For the routine, a dipstick method can also be used, including leukocyte esterase test, or nitrite reaction.

    Table 1. Classification of prostatitis according to NIDDK/NIH



























    IAcute bacterial prostatitis (ABP)
    IIChronic bacterial prostatitis (CBP)
    IIIChronic pelvic pain syndrome (CPPS)
    A Inflammatory CPPS: WBC in EPS/voided bladder urine-3 (VB3) or semen
    B Noninflammatory CPPS: no WBC/EPS/VB3/semen
    IVAsymptomatic inflammatory prostatitis

    Diagnosis
    Disease history, physical examination and urine analysis by dipstick including white and red blood cells as well as nitrate reaction is recommended for routine diagnosis.

    In case of suspicion of pyelonephritis, evaluation of the upper urinary tract may be necessary to rule out upper urinary tract obstruction or stone disease.















































































































    DiagnosisMost Frequent
    pathogens
    Initial, empiric antimicrobial
    therapy
    Therapy duration
    Cystitis, acute,
    Uncomplicated
    E.coli
    Klebsiella
    Proteus
    Staphylococcus
    Trimethoprim/ sulfamethoxazole
    Fluroquinolonea
    Alternatives:
    Fosfomycin
    Nitrofurantoin
    3 days
    3 days
    1 day
    7 days
    Pyelonephritis, acute,
    uncomplicated
    E.coli
    Proteus
    Klebsiella
    Other Enterobacteria
    Staphylococcus
    Fluroquinolone
    Cephalosporin Gr. 2b/3a
    Alternatives
    Aminopenicillin / BLI
    Aminoglycoside
    7-10 days
    UTI with complicatingE.coli Fluoroquinolone3-5 days after
    defervescence or
    control/ examination of
    complicating factor
    Factors
    Nosocomial UTI
    Pyelonephritis, acute,
    Complicated
    Enterococcus
    Staphylococcus
    Klebsiella
    Proteus
    Enterobacter
    Aminopenicillin / BLI
    Celphalosporin Gr. 2
    Celphosporin Gr. 3 a
    Aminoglycosides
    In case of failure of initial therapy
    within 1-3 days or in clinically
    severe cases:
    Other Enterobacteria Pseudomonas (Candida)Anti-Pseudomonas active: Fluroquinolone, if not used initially
    Acylaminopenicillin/BLI
    Cephalosporin Gr. 3B
    Carbapenem
    + Aminoglycoside
    In case of Candida
    Fluconazole
    Amphotericin B
    Prostatitis, acute,
    chronic
    E.coliFluroquinoloneaAcute : 2 weeks
    Epididymitis,acuteOther EnterobacteriaAlternative in acute bacterial
    prostatitis
    PseudomonasCephalosporin Gr. 2Chronic : 4-6 weeks or
    longer
    EnterococcusCephalosporin Gr. 3a/b
    StaphylococcusIn case of Chlamydia or
    Ureaplasma:
    ChlamydiaDoxycyline
    Ureaplasma Macrolide
    Urosepsis E.coliCephalosporin Gr. 3a/b3-5 days after
    defervescence or
    control/ elimination of
    complicating factor
    Other EnterobacteriaFluorquinolonea
    After urological interventions -Anti-Pseudomonas active
    Acylaminopenicillin/BLI
    pathogens:
    Proteus
    Serratia
    Carbapenem
    Aminoglycosides
    Enterobacter
    Pseudomonas

    a Fluroquinolone with mainly renal excretion; BLI= B- lactamase inhibitor. B 1 st,2nd and 3rd generation respectively (3a - without; 3b - with anti-Pseudomonas activity)

    Treatment

    Treatment of UTI is dependent on a variety of factors. An overview of most frequent pathogens, antimicrobial agents and duration of treatment in various conditions is given in table 2. Patients with recurrent UTI may be recommended prophylactic treatment. The following regimens have a documented effect in preventing recurrent UTI in women (table 3).



















    AgentDose
    Standard regimens (taken at bedtime) Trimethoprim / sulfamethoxazole

    Trimethoprim




    40/200mg/day or

    3 times weekly

    100mg/days
    Nitrofurantoin

    Others

    Cephalexin

    Norfloxacin

    50mg/day



    125 or 250 mg/day

    200 mg/day
    Ciprofloxacin125 mg/day



    Special situations:

    • UTI in pregnancy. Asymptomatic bacteriuria is treated with a 7 day course based on sensitivity testing. For recurrent symptomatic infections, either cephalexin 125-250 mg/day or nitrofurantoin 50 mg/day may be used.

    • UTI in postmenopausal women. In women with recurrent infection intravaginal estriol is recommended. If this does not work, in addition antibiotic prophylaxis is indicated.



    • UTI in children. Treatment perioud should be extended to 7-10 days. Tetracyclines and fluroquinolones should not be used due to effects on teeth and cartilage.



    • Acute uncomplicated UTI in young men. The treatment should last at least 7 days.



    • UTI in diabetes mellitus and renal insufficiency. After treatment, a prophylactic regimen may be recommended afterwards.



    • Complicated UTI due to urological disorders. The underlying disorded must be managed if permanent cure is to be expected. In order to avoid inducing resistant strains, treatment should be guided by urine culture whenever possible.



    • Sepsis syndrome in Urology (urosepsis).


    Patient with UTI may develop sepsis. Early signs of systemic inflammatory response (fever or hypothermia, tachycardia, tachypnea, hypotension,oliguria, leukopenia) should be recognized as the first signs of possible multiorgan failure. In conjunction with appropriate antibiotic therapy, life supporting therapy in collaboration with an intensive care specialist may be necessary. Any obstruction in the urinary tract needs to be drained.

    Follow-up of patients with UTI

    for follow-up after uncomplicated UTI and pyelonephritis in women, a urinanalysis by dipstick is enough for routine use.

    In women who will have recurrence within 2 weeks, repeated urinary culture with antimicrobial testing and evaluation of the urinary tract is recommended.

    In the elderly, newly developed recurrent UTI may warrant a full evaluation of the urinary tract.

    In men with UTI, a urologic evaluation should be done when the patient is in adolescence, in cases with recurrent infection and in all causes with pyelonephritis. Also patients with prostatitis, epididymitis and orchitis should follow these recommendations.

    In children, investigations are indicated after two episodes of UTI in girls and one episode in boys. Recommended investigations are ultrasonography of the urinary tract supplemented by voiding cystourethrography.

    Urethritis

    Symptomatic urethritis is characterized by dysuria and purulent discharge

    Diagnosis

    The Gram stain of secretion or urethral smear showing more than 5 leukocytes per high power field (HPF) (1,000) and eventually gonococci located intracellularly as Gram-negative diplococci indicate a pyogenic urethritis. A positive leukocyte esterase test or more than 10 leukocytes per high-power field (400) in the first voiding urine specimen are diagnostic.

    Therapy

    The following guidelines for therapy comply with the recommendations of the Centre for Disease Control and Prevention (1998).

    For the treatment of gonorrhea the following antimicrobials can be recommended:













    Cefixime 400 mg orally

    As a single dose

    Cefriaxone 250 mg

    i.m. As a single dose



    (i.m. with local anaesthetic)





    Ciprofloxacin 500 mg

    orally as a single dose



    Ofloxacin 400 mg orally

    as single dose




    As gonorrhea is frequently accompanied by chalamydial infection, an antichlamydial active therapy should be added. The following treatment has been successfully applied in C. trachomatis infections :

















    First choiceSecond choice
    Azithromycin

    1 g (=4 caps.@250 mg) orally

    as single dose

    Erythromycin

    500 mg orally 4 times daily for 7 days
    Doxycycline

    10 mg 2 times daily orally for 7 days
    Ofloxacin

    200 mg orally for 7 days

    if therapy fails, one should consider infections by T. vaginalis and / or Mycoplasma, which can be treated with a combination of metronidazole (2 g orally as single dose) and erythromycin (4 times daily 500 orally for 7 days).

    Prostatitis, Epididymitis and Orchitis

    Prostatitis

    Treatment

    • Acute bacterial prostatitis can be a serious infection and parenteral administration of high doses of bactericidal antibiotic such as aminoglycosides and a penicillin derivative or a 3rd generation cephalosporin are required until defervescence and normalization of infection parameters. In less severe cases a fluoroquinolone may be given orally for at least 10 days.

    • In chronic bacterial prostatitis and chronic inflammatory pelvic pain syndrome, a fluoroquinolone or trimethorpim should be given orally for 2 weeks after the initial diagnosis. Then the patient should be reassessed and antibiotics only continued if pretreatment cultures were positive or if the patient reports positive effect of the treatment. A total treatment period of 4-6 weeks is recommended.


    Epididymitis, Orchitis

    The majority of cases of epididymitis are due to common urinary pathogens. Bladder outlet obstruction and urogenital malformations are risk factors for this type of infection.

    Treatment

    Prior to antimicrobial therapy a urethral swab and midstream urine should be obtained for microbiological investigation. Fluoroquinolones, preferably those which react well against C. trachomatis (e.g. ofloxacin, levofloxacin) should be first choice drugs because of their broad antibacterial spectra and their.

    Table 4. Recommendations for perioperative antibacterial prophylaxis in urology


































































    ProcedureMost common
    pathogens (s)
    Antibiotic(s) of choiceAlternative
    antibiotic(s)
    Remarks
    Open
    operations
    urinary tract
    including bowel
    segments
    Enterobacteria
    Enterococci
    Anaerobes
    Wound infection:
    Staphylococci
    Enterbacteria
    Enterococci
    Wound infection:
    staphylococci
    Staphylococci
    Staphylococci
    Aminopenicillin + BLI
    Cephalosporin 20
    +
    Metronidazole
    In high-risk patients:
    Cephalosporin3
    Acylaminopenicillin +
    BLI
    In all patients
    Urinary tract
    without bowel
    segments
    Fluoroquinolone
    Cephalosporin 20
    Aminopenicilin +BLI
    in high-risk patients:
    Cephalosporin3
    Acylaminopenicillin +
    BLI
    in patients with
    increased risk of
    infection
    Implant /
    prosthesis:
    penis, sphincter
    Reconstructive
    genital
    operation
    Cephalosporin 10
    /20
    Cephalosporin 10
    /20
    in all patients
    in secondary operations
    & in patients with
    increased risk of
    infection
    Other
    interventions
    outside of the
    Cephalosporin 10
    /20
    in patients with
    increased risk of
    infection
    urinary tract
    Endoscopic –
    instrumental
    operations
    Urethra,
    prostate,
    bladder, ureter,
    kidney, incl.
    percutaneous
    litholapaxy and
    ESWL
    Enterobacteria
    Staphylococci
    Enterococci
    Fluoroquinolone
    Aminopenicillin + BLI
    Cephalosporin 20
    Fosfomycin
    Trometamol
    Cotrimozazole
    Aminoglycoside
    In patients with
    increased risk of
    infection
    Diagnostic
    intervention
    Transrectal
    biopsy of the
    prostate (with
    thick needle)
    Enterobacteria
    Enterococci
    Anaerobes
    Streptococci
    Enterobacteria
    Enterococci
    Staphylococci
    Fluoroquinolonea
    Aminopenicllin + BLI
    Cephalosorin 20
    +
    Metronidazole
    Fluoroquinolonea
    Aminopenicillin + BLI
    Cephalosporin 20
    Aminoglycoside
    Cotrimozazole
    In all patients
    Perineal biopsy
    of the prostate,
    urethrocystosc
    opy,
    ureterorenosco
    py,
    percutaneous
    pyeloscopy,
    laparoscopic
    procedures
    CotrimoxazoleIn patients
    with increased risk of
    infection

    BLI = B- Lactamase inhibitor, ESWL- extracorporeal shock-wave lithotripsy. 10 ,20 ,30 = 1st, 2nd, 3rd generation respectively.

    11. Fluroquinolone with sufficient renal excretion

    Favorable penetration into the tissues of the urogenital tract. In case C. trachomatis has been detected as etiologic agent, treatment could also be continued with doxycycline 200 mg/day for a total treatment period of at least 2 weeks. Macrolides may be alternative agents. In case of C .trachomatis infection, the sexual partner should be treated as well.

    Antibiotics and α Blockers in combination

    Urodynamic studies have shown increase urethral closing pressure in patients with chronic prostatitis. A combination treatment of α blockers and antibiotics is reported to have a higher cure rate than antibiotics alone in inflammatory CPPS. This is a treatment option favored by many urologists.

    In general, surgery should be avoided in the treatment of prostatitis patients except for drainage of prostatic abscesses.

    Perioperative Antibacterial Prophylaxis in Urological Surgery

    The main aim of antimicrobial prophylaxis in urology is to prevent symptomatic / febrile genitourinary infections, such as acute pyelonephritis, prostatitis, edpididymitis and urosepsis as well as serious wound infections.

    Antibiotic prophylaxis is recommended only for a maximum of 24 hours after surgery in most situations. More rampant use leads to antibiotic resistance and places an additional economic burden. Prophylaxis does not substitute for poor surgical asepsis.

    Guidelines by The Ministry of Health and Family Welfare :

    Prof. Rajesh Ahlawat
    Chairman,
    Department of Urology & Kidney Transplant,
    Medanta Medicity
    Reviewed By:
    Dr Anup Kumar Gupta
    Head of Department
    Department of Urology
    VMMC and Safdarjang Hospital,
    New Delhi

    CephalexinCiprofloxacinDr Anup Kumar GuptaguidelinesNorfloxacinProf Rajesh AhlawatPyuriatreatment guidelinesUrethritisUrinary and male genital tract infectionsUrosepsisUTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok